Fremanezumab Recruiting Phase 4 Trials for Major Depressive Disorder (MDD) / Migraine / Coronavirus Disease 2019 (COVID‑19) Prevention

IndicationsStatusPurposePhase
RecruitingPrevention4
clinicaltrials.gov IdentifierTitleDrugs
NCT04041284A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder